Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. The most recent global cancer burden estimated almost 760,000 deaths in 2022 alone. Notable advances over the past year in the management of HCC include new…

Preview only. Read the full abstract at the source